How MyGlo Reagent Reader boosts research at Tridek-One

SFBN Feed: Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors https://lnkd.in/gjwjd4fR PHILADELPHIA & SAN FRANCISCO–(BUSINESS WIRE)–Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (“BMS”) to [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

ThirdLaw Molecular is now Ladder Bio Inc.! We are excited to celebrate the rebrand and the close of a $5.5M Seed round led by Medical Excellence Capital, LLC, with participation from Hatch Biofund Management. Alongside the financing, Eric Heil joins as Chief Executive Officer, and David Scheer and Brian Halak join the Board. Ladder Bio is pioneering Spiroligomer™ therapeutics - ladder‑shaped, peptide‑like molecules designed to open new chemical space and tackle targets long considered undruggable. SmartGateVC co‑led the company’s pre‑seed and we are proud to keep backing Prof. Christian Schafmeister and the team as they build a new therapeutic modality. Read the announcement: https://lnkd.in/egmMrErQ and coverage by Philadelphia Business Journal: https://lnkd.in/ekE9MwRr.

The Valuation Paradox | A clip from my Substack post, Video Recap: United Therapeutics’ Second Growth Act. Watch it here: https://lnkd.in/emxpx48r

📰 𝗟𝗔𝗧𝗘𝗦𝗧 𝗡𝗘𝗪𝗦: The Philippine Board of Investments (BOI), through Green Lane Certification under Executive Order No. 18, has expedited the business operations of Exin Therapeutics, Inc. for its groundbreaking neurotherapeutics laboratory integrated with an AI drug discovery platform. Stay in the loop and read all about it here👉 https://lnkd.in/gYC53B-W #MakeItHappenInThePhilippines #PhilippinesBusiness #LatestNews #BusinessUpdates

While many boast about how they leverage target genetics to increase preclinical success rates from 2 to 8%, we provide a target connectivity powered neuromap that has a 69% to 97% Phase III Clinical Failure Elimination rate to our academic, biotech and pharma partners. Discover how our biological intelligence approach can de-risk and accelerate your drug discovery, repurposing, or foundation model evaluation efforts by reviewing the 11-slide presentation provided here or contacting us.

Navigating a New Volatility Landscape: Opportunities in $LEG, $MAR, $YUM, $MDT, $RRC, $CGTX, and $NFBK: Exploring potential portfolio moves amid shifting market dynamics, focusing on Leggett Platt ($LEG), Marriott ($MAR), Yum Brands ($YUM), Medtronic ($MDT), Range Resources ($RRC), Cognition Therapeutics ($CGTX), and Northfield Bancorp ($NFBK). https://lnkd.in/gc9CCSWv

📢 𝟒 𝐃𝐀𝐘𝐒 𝐓𝐎 𝐆𝐎 The countdown is on for the LNP Characterisation & Analytical Development Summit, and the excitement is building fast. Excited to meet the experts pushing the boundaries of how we measure, understand, and optimise LNPs — including: 🔬Pfizer 🧪ATEM Structural Discovery 🧫Sanofi 🥼Spectradyne 🧪Novo Nordisk 🔬Sartorius BIA Separations 🥼Tessera Therapeutics 🧫NanoFCM 🔬AbbVie 🧪Intertek 🥼Prime Medicine, Inc. 🔬SCIEX 🧫Takeda 🧪InProcess-LSP From advanced particle analysis to next-gen structural profiling and high-resolution QC tools, these teams are redefining what high-confidence LNP characterisation looks like. If you're focused on elevating analytical depth, strengthening quality frameworks, or unlocking clearer structure–function insights, this is the place to be. 📍 Boston | Nov 18–20 #LNPDevelopment #AnalyticalDevelopment #LNPCharacterisation #RNAtherapeutics #DrugDelivery #LNPCAD #LNPCharacterisationAndAnalyticalDevelopmentSummit

What’s not working, what is working, and what’s next in life sciences commercialization. Beghou Partner Melissa McDevitt will be moderating a webinar titled “Rethinking Life Sciences Commercialization for 2026,” where findings from Beghou’s Commercialization That Works research will be shared. The session will feature: 🎙️Amit Grover, AVP, Commercial Excellence, Stemline Therapeutics, a Menarini Company 🎙️ Marcos Mendell, Partner, Beghou Gain practical insights on: ✔️ Key drivers and obstacles across commercial functions ✔️ Determining how early is “early enough” for launch planning ✔️ Lessons large and small companies can learn from each other ✔️ Case studies and actionable strategies for commercialization success Register to receive the recording, slides, and full report even if you’re unable to attend live. Registration link: https://gag.gl/dTBh7U

Perpetual Medicines, a leader in computational peptide therapeutics, needed a highly specialized leader. Previous searches stalled, so they turned to us. Within two months, the role was filled, strengthening their team and market position. 🔗 Read the full story: https://lnkd.in/eKGTN8A7 #Acceler8 #CaseStudy #PerpetualMedicines #TargetedSearch #ExecutiveSearch #TalentSolutions

What’s not working, what is working, and what’s next in life sciences commercialization. Beghou Partner Melissa McDevitt will be leading a webinar titled “Rethinking Life Sciences Commercialization for 2026,” where we will present some insights from Beghou’s Commercialization That Works research. The session will feature: 🎙️Amit Grover, AVP, Commercial Excellence, Stemline Therapeutics, a Menarini Company 🎙️ Marcos Mendell, Partner, Beghou You’ll gain practical insights on: ✔️ Key drivers and obstacles across commercial functions ✔️ Determining how early is “early enough” for launch planning ✔️ Lessons large and small companies can learn from one another ✔️ Case studies and actionable strategies for commercialization success Register to receive the recording, slides, and full report even if you can’t attend live. Registration link: https://gag.gl/dTBh7U